BVX — Bivictrix Therapeutics Cashflow Statement
0.000.00%
- £6.19m
- £4.70m
Annual cashflow statement for Bivictrix Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | Interim Report | ARS | ARS | ARS |
| Standards: | — | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -0.49 | -2.53 | -2.97 | -3 |
| Depreciation | ||||
| Non-Cash Items | 0.004 | 0.865 | 0.123 | 0.069 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 0.32 | -0.164 | 0.3 | 0.809 |
| Change in Accounts Receivable | ||||
| Change in Accounts Payable | ||||
| Change in Payable / Accrued Expenses | ||||
| Other Operating Cash Flow | ||||
| Cash from Operating Activities | -0.165 | -1.78 | -2.4 | -1.96 |
| Capital Expenditures | -0.063 | -0.046 | -0.389 | -0.005 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | — | — | 0.01 | 0.022 |
| Sale of Fixed Assets | ||||
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | -0.063 | -0.046 | -0.379 | 0.017 |
| Financing Cash Flow Items | -0.018 | -0.437 | 0 | -0.082 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 0.961 | 7.03 | 0 | 1.94 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 0.733 | 5.2 | -2.78 | -0.008 |